Antibody-Drug Conjugates | Special Topics | Trends and Market Dynamics – Multi-indication | G7 | 2022
Antibody-drug conjugates have demonstrated their efficacy in the treatment of a broad range of tumor types, establishing the drug class as a versatile weapon against cancer. The approval of antibody-drug conjugates continues to transform the treatment paradigm for many oncology indications at an incredible rate. This Special Topics report provides a comprehensive market forecast of current and emerging antibody-drug conjugates and analyzes the market trends and dynamics in a range of oncology indications.
QUESTIONS ANSWERED
- What is the timeline and current landscape for approved antibody-drug conjugates? What are the trends in each key oncology indication?
- How will emerging antibody-drug conjugates be positioned in the market? How will the indication-specific market trends and dynamics evolve?
- What is the commercial potential of current and emerging antibody-drug conjugates by brand, indication, combination type, and geography? How will the market evolve over the 2021-2031 forecast period?
GEOGRAPHIES
United States, EU5, Japan.
EPIDEMIOLOGY
Drug-treated patient populations by brand, indication, combination type, and geography for indications for which antibody-drug conjugates are approved or forecast for approval.
FORECAST
10-year, annualized, drug-level sales of antibody-drug conjugates through 2031, segmented by indication, combination type, and geography.
KEY DRUGS COVERED
Currently approved agents targeting HER2, TROP-2 and CD79b.
EMERGING THERAPIES
Phase III
PRODUCT DESCRIPTION
Clarivate’s Special Topics reports assess key trends in dynamic disease areas. This report offers a comprehensive market forecast of the antibody-drug conjugate landscape in relevant oncology indications.
